The use of SSRIs in children and adolescents
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Introduction Depressive disorders are prevalent among young people [1,2] and are frequently untreated or inadequately treated [3]. The use of antidepressants in the management of depression in children and adolescents is contentious. Selective serotonin reuptake inhibitors (SSRIs) had been widely used in paediatric depression until warnings about their use were issued following concerns that children and adolescents who had participated in trials evaluating the effectiveness of SSRIs were at an increased risk of self-harm. This resulted in comprehensive reviews of the trials by government regulatory agencies which all concluded that only fluoxetine should be recommended for use in children and adolescents with depressive disorders [4–7]. Claims and counter claims about the effectiveness of SSRIs and risk related to their use have followed [8–13]. Concerns have been raised that if antidepressant use is limited young people could be deprived of effective treatments for a condition that carries with it considerable morbidity and mortality [8,9,14]. Recent research has suggested that pessimism about effective treatments has resulted in reluctance on the part of patients to seek help [15]. Further, lower rates of depressive disorder diagnoses [15] may indicate that clinicians are reluctant to make this diagnosis, perhaps due to uncertainty about effective treatments. The two key questions when considering the use of SSRIs in the treatment of children and adolescents with depressive disorder are, do they work and are they well tolerated? Answering these questions requires consideration of the evidence. Do selective serotonin reuptake inhibitors work? We undertook a Cochrane systematic review to evaluate the evidence about the effectiveness and risk of this class of medication for children and adolescents [16]. Twelve trials met the inclusion criteria for our review. The outcome ‘response’ was reported in all trials. This was a binary outcome created from a cut-point on a continuous depression scale. Both the scale and cut-point varied between trials. The pooled treatment effect of all SSRI compounds on the outcome ‘response’ demonstrated that a greater percentage of participants receiving SSRIs responded compared with those receiving placebo [relative risk (RR) 1.28; 95% confidence interval (CI) 1.17, 1.41] (Fig. 1).Figure 1: Relative risk of response to selective serotonin reuptake inhibitors compared with placeboThere was evidence that effectiveness of SSRIs on ‘response’ varied by compound (with 81.3% of the variation across SSRI compound effect estimates due to heterogeneity rather than chance; P = 0.001). There was a statistically significant difference in the percentage of children and adolescents who ‘responded’ when receiving fluoxetine compared with placebo (RR 1.86; 95% CI 1.49, 2.32). The percentage of those ‘responding’ while on fluoxetine ranged between 41 and 61% compared with a range of 20–35% in those on placebo. Depressive symptom scores [Children's Depression Rating Scale-Revised scale (CDRS-R); range 17–113] were also statistically significantly lower for those receiving fluoxetine compared with placebo at the end of treatment [ranging between 8 and 12 weeks of treatment; treatment effect 5.63 (95% CI −7.38, −3.88)]. For paroxetine, there was no statistically significant difference in the percentage of children and adolescents who ‘responded’ to paroxetine compared with those who ‘responded’ to placebo (RR 1.09; 95% CI 0.95, 1.26). There was a lack of consistency for both sertraline and citalopram. There was no statistically significant difference in ‘response’ rate between the sertraline and control groups (RR 1.17; 95% CI 1.00, 1.36). However, depressive symptom scores were significantly lower in the sertraline group (treatment effect CDRS-R 3.56; 95% CI −6.69, −0.42). There was a statistically significant difference in the percentage of children and adolescents who ‘responded’ when receiving citalopram/escitalopram (RR 1.30; 95% CI 1.02, 1.67), compared with placebo but no significant difference in depressive symptom score (CDRS-R). Functioning is perhaps the most relevant outcome for young people as it measures their ability to sustain school/work, interpersonal relations, and social functioning on a day-to-day basis [17]. There was no evidence that SSRIs were effective in improving functioning. What are the strengths and weaknesses of the evidence base? It is important to be cautious when interpreting the results of our review. The interpretation of the outcome ‘response’, the selection of patient outcomes, the clinical significance of treatment effects, and other issues of internal and external validity all need consideration. Outcome measurement In the search for effective treatments, the ideal goal is a resolution of symptoms (i.e., remission) and a return to normal function. In the trials in our review, remission or functioning were inconsistently reported, not reported, or not collect
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Childhood and adolescent depression: a review of the past 10 years, Part I
BIRMAHER, B., RYAN, N. D., WILLIAMSON, D. E., BRENT, D. A., KAUFMAN, J., DAHL, R. E., PEREL, J., & NELSON, B. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199611000-00011 · Cited by 2,076
Lewinsohn, P. M., Hops, H., Roberts, R. E., Seeley, J. R., & Andrews, J. A. (1993) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.102.1.133 · Cited by 1,547
Birmaher, B., & Brent, D. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318145ae1c · Cited by 1,056
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Kovacs, M. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790140019002 · Cited by 712
Adolescent suicidal ideation and attempts: Prevalence, risk factors, and clinical implications.
Lewinsohn, P. M., Rohde, P., & Seeley, J. R. (1996) · Clinical Psychology: Science and Practice · doi:10.1111/j.1468-2850.1996.tb00056.x · Cited by 661
Goodyer, I., Dubicka, B., Wilkinson, P., Kelvin, R., Roberts, C., Byford, S., Breen, S., Ford, C., Barrett, B., Leech, A., et al. (2007) · BMJ · doi:10.1136/bmj.39224.494340.55 · Cited by 352
Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management
Cheung, A. H., Zuckerbrot, R. A., Jensen, P. S., Ghalib, K., Laraque, D., Stein, R. E. K., & and the GLAD-PC Steering Group (2007) · Pediatrics · doi:10.1542/peds.2006-1395 · Cited by 336
Outcome selection bias in meta-analysis
Williamson, P. R., Gamble, C., Altman, D. G., & Hutton, J. L. (2005) · Statistical Methods in Medical Research · doi:10.1191/0962280205sm415oa · Cited by 188
Using epidemiological data to model efficiency in reducing the burden of depression
Andrews, G., Sanderson, K., Corry, J., & Lapsley, H. M. (2000) · The Journal of Mental Health Policy and Economics · doi:10.1002/mhp.96 · Cited by 110
Cited by
Newer generation antidepressants for depressive disorders in children and adolescents
Hetrick, S. E., McKenzie, J. E., Cox, G. R., Simmons, M. B., & Merry, S. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004851.pub3 · Cited by 291
Self-citationRice, F., Riglin, L., Thapar, A. K., Heron, J., Anney, R., O’Donovan, M. C., & Thapar, A. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3338 · Cited by 167
Cox, G. R., Callahan, P., Churchill, R., Hunot, V., Merry, S. N., Parker, A. G., & Hetrick, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008324.pub2 · Cited by 70
Self-citationHetrick, S. E., Goodall, J., Yuen, H. P., Davey, C. G., Parker, A. G., Robinson, J., Rickwood, D. J., McRoberts, A., Sanci, L., Gunn, J., et al. (2017) · Crisis · doi:10.1027/0227-5910/a000422 · Cited by 31
Self-citation
Metadata
- Authors
- Hetrick, S. E., McKenzie, J. E., & Merry, S. N.
- Venue
- Current Opinion in Psychiatry
- Published
- 2010-01
- Volume
- 23
- Issue
- 1
- Pages
- 53-57
- ISSN
- 0951-7367 (ISSN-L)
- OpenAlex
- W2049618851
- Cited by
- 36
- References
- 11
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.